Clearstead Advisors’s INmune Bio INMB Stock Holding History

Clearstead Advisors’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28	Buy	+17	New	+$24	﹤0.01%	3556
2025 Q2	–	Sell	-590	Closed	-$4.61K	–	2811
2025 Q1	$4.61K	Buy	590 +100	+20%	+$794	﹤0.01%	1768
2024 Q4	$2.29K	Hold	490	–	–	﹤0.01%	1830
2024 Q3	$2.64K	Hold	490	–	–	﹤0.01%	1812
2024 Q2	$4.32K	Hold	490	–	–	﹤0.01%	1706
2024 Q1	$4.86K	Buy	490 +70	+17%	+$846	﹤0.01%	1179
2023 Q4	$4.73K	Hold	420	–	–	﹤0.01%	1169
2023 Q3	$2.84K	Hold	420	–	–	﹤0.01%	1179
2023 Q2	$3.81K	Hold	420	–	–	﹤0.01%	1076
2023 Q1	$2.71K	Buy	+420	New	+$3.38K	﹤0.01%	1091

Other funds holding INMB

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Clearstead Advisors's INMB Position: Q2 2026 in Review

Clearstead Advisors opened a new position in INmune Bio (INMB) in Q2 2026: 17 shares worth $28. The stake represents ﹤0.01% of the portfolio and ranks #3556 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in INMB as recently as Q1 2025.

Clearstead Advisors first reported a position in INMB in Q1 2023 and has held it in 10 quarters since. The position peaked at $4.86K in Q1 2024. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

Clearstead Advisors held 17 shares of INmune Bio worth $28 as of Q2 2026.
INmune Bio was a new Clearstead Advisors position in Q2 2026.
INmune Bio made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3556 holding.
Clearstead Advisors first reported a position in INmune Bio in Q1 2023 and has held it in 10 quarters since.
Clearstead Advisors's INmune Bio position peaked at $4.86K in Q1 2024.
83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.